NEW CASES DEATHS HOSPITALIZATIONS
1ST 3,045 5 1,075
2ND 2,361 5 1,096
3RD 2,293 20 1,138
4TH 3,734 16 1,242
5TH 3,672 19 1,279
6TH 3,930 17 1,370
7TH 4,283 13 1,383
8TH 3,031 8 1,433
9TH 2,919 6 1,437
10TH 2,622 22 1,503
11TH 3,498 28 1,573
12TH 3,865 23 1,648
13TH 3,810 19 1,645
Media Contact: media@ph.lacounty.gov - (213) 240-8144
Following the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) approval of an additional dose of the Pfizer and Moderna COVID-19 vaccines for immunocompromised people, Los Angeles County will begin administering third doses to those who qualify tomorrow. The FDA has amended the Emergency Use Authorization for these vaccines to allow for a third dose which can be administered at least 28 days following the second dose of the vaccine.
Ideally individuals should be vaccinated with the same vaccine they received for the first and second dose, but if that is not possible, receiving a third dose with another mRNA vaccine is acceptable.
Although the Pfizer and Moderna vaccines work very well in the majority of individuals, there is evidence that individuals who are severely immunocompromised are not fully protected after receiving two doses and this small, vulnerable group may benefit from a third dose. Certain medical conditions or the treatments used for specific conditions may prevent the immune system from responding adequately to two doses of the vaccine and therefore require an additional dose to provide adequate protection from COVID-19. Individuals who qualify for a third dose include organ transplant recipients, people undergoing cancer treatment, people with advanced or untreated HIV and those on certain immunosuppressive medications.
The Los Angeles County Department of Public Health (Public Health) encourages individuals who qualify for a third dose to speak to their healthcare provider to confirm their eligibility and get vaccinated. Third doses of the vaccines will be accessible through vaccination sites that currently offer Pfizer or Moderna vaccines. Eligible individuals will be able to provide a self-attestation that they have a qualifying medical condition at these sites.
A follow-up dose is not currently recommended for those who have received a single dose of the Johnson & Johnson vaccine. The FDA is still evaluating data on the effectiveness of the Johnson & Johnson vaccine in immunocompromised individuals. COVID-19 vaccine booster doses are also not recommended for the general public at this time.
No comments:
Post a Comment
For now, we're opening this blog to Anonymous comments. This will continue as long as civility rules. Disagree as you may, just keep it clean and stay on topic. No profanity, and no name calling. We reserve the right to moderate such comments, though the person who made it may come back and reword their message in a more civil way.